Laurion Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Laurion Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-524	Closed	-$373K	–	365
2024 Q4	$373K	Buy	+524	New	+$440K	0.01%	235
2022 Q2	–	Sell	-10,000	Closed	-$6.98M	–	660
2022 Q1	$6.98M	Buy	+10,000	New	+$6.33M	0.09%	141
2021 Q3	–	Sell	-443	Closed	-$247K	–	840
2021 Q2	$247K	Buy	+443	New	+$224K	﹤0.01%	626
2021 Q1	–	Sell	-427	Closed	-$206K	–	872
2020 Q4	$206K	Buy	+427	New	+$230K	﹤0.01%	583
2019 Q4	–	Sell	-200	Closed	-$55K	–	1171
2019 Q3	$55K	Sell	200 -4,452	-96%	-$1.32M	﹤0.01%	960
2019 Q2	$1.46M	Buy	+4,652	New	+$1.55M	0.01%	501
2019 Q1	–	Sell	-4,285	Closed	-$1.76M	–	1224
2018 Q4	$1.6M	Buy	4,285 +20	+0.5%	+$7.32K	0.03%	469
2018 Q3	$1.72M	Sell	4,265 -3,913	-48%	-$1.49M	0.02%	569
2018 Q2	$2.82M	Hold	8,178	–	–	0.02%	505
2018 Q1	$2.82M	Buy	8,178 +600	+8%	+$209K	0.02%	536
2017 Q4	$2.85M	Buy	7,578 +2,900	+62%	+$1.17M	0.01%	675
2017 Q3	$2.09M	Sell	4,678 -500	-10%	-$238K	0.01%	760
2017 Q2	$2.54M	Buy	5,178 +1,520	+42%	+$665K	0.01%	746
2017 Q1	$1.42M	Buy	3,658 +1,758	+93%	+$652K	0.01%	673
2016 Q4	$697K	Buy	+1,900	New	+$723K	0.01%	771

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Laurion Capital Management's REGN Position: Q1 2025 in Review

Laurion Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 524 shares — an estimated $373K sold.

Laurion Capital Management first reported a position in REGN in Q4 2016 and held it in 15 quarters. The position peaked at $6.98M in Q1 2022. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Laurion Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Laurion Capital Management sold 524 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $373K.
Laurion Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 15 quarters.
Laurion Capital Management's Regeneron Pharmaceuticals position peaked at $6.98M in Q1 2022.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Laurion Capital Management's 13F filing for Q1 2025, filed 15 May 2025.